arrow
C

Chao-Hung Hung

kaohsiung chang gung memorial hospital
H指数:31
被引数:4,413

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Proton Beam Therapy Boosts Outcomes of Atezolizumab/Bevacizumab in Advanced Hepatocellular Carcinoma: A Propensity Score Analysis

质子束疗法提升了阿替利珠单抗/贝伐珠单抗在晚期肝细胞癌中的疗效:一项倾向性评分分析

2025-12-020
PRE
Prognostic Nutritional Index Predicts Outcomes in Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab: A Propensity Score-matched Analysis

预后营养指数预测接受阿替利珠单抗和贝伐珠单抗治疗的肝细胞癌患者结局:一项倾向性评分匹配分析

2025-12-010
PRE
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study

丙型肝炎病毒清除对伴有或不伴有活动性肝细胞癌患者的生存影响:一项全国性队列研究

2025-11-140
PRE
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan

Sofosbuvir/Velpatasvir治疗对2型糖尿病和慢性丙型肝炎患者肝外表现的影响: 来自台湾全国丙型肝炎病毒登记处的见解

2025-06-200
OAAI
Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real-World Experience From the Nationwide Taiwan Hepatitis C Virus Registry

丙型肝炎病毒清除对心血管风险的影响: 来自全国台湾丙型肝炎病毒登记处的真实经验

2025-05-240
OAAI
Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de novo liver complications in hepatitis C

Hong, C.-M.; Su, T.-H.; Hsu, S.-J.; Tseng, T.-C.; Liu, C.-H.; Yang, H.-C.; Kao, J.-H.; Chen, P.-J.; Cheng, P.-N.; Hung, C.-H.; 等. 将中性粒细胞与淋巴细胞比值加入Pre-DAA FIB-4不会增加对丙型肝炎患者新发肝并发症的预测价值。中华医事杂志. 2024; 已录用. [Google Scholar] [CrossRef] [PubMed]

2024-11-020
OAAI
Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensus
2024-11-011
OAAI
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan
2024-01-213
OAAI